EUVIMEDEUVIMED entdecken
Open Access

Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder

Holly E Richter iD, Benjamin Chastek iD, Adam Carrera iD, Christina Steiger iD, Daniel Snyder, Laleh Abedinzadeh iD, Tim Bancroft iD, Jeffrey Nesheim iD, Roger R Dmochowski iD, Adonis K Hijaz iD, Jeffrey Frankel iD

Journal of Comparative Effectiveness Research · 2026

DOI: 10.57264/cer-2025-0054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026. Verfasst von Holly E Richter und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Cholinergic Antagonists, Health Care Costs. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Anticholinergic burden (ACB) is associated with profound clinical and economic burden; however, anticholinergic medications are often prescribed for overactive bladder (OAB). This analysis assessed risk of adverse health outcomes and costs associated with ACB among patients with OAB. Materials & methods: Adults with ≥1 pharmacy claim for ≥1 OAB anticholinergic medication and continuous coverage for ≥6 months before and after the first prescription fill date for OAB anticholinergic medication (index) from January 2010 to November 2021 in the Optum Research Database were included. Daily ACB scores were calculated postindex. The impact of ACB on risk of certain adverse health outcomes was examined using Cox proportional hazards regression with categorical and piecewise linear specifications for ACB. Time-varying total ACB association with healthcare costs was evaluated with marginal structural models.

Results

Overall, 428,142 patients were included in the analysis; mean (SD) age was 65.2 (14.9) years. Mean (SD) preindex ACB was 0.53 (1.44) points/day. Postindex, OAB medications accounted for 61.0% (95% CI: 60.9%–61.1%) of total ACB. Adjusted hazard ratios for urinary tract infection (UTI), urinary retention, delirium/drowsiness, cognitive impairment, falls/fractures and cardiovascular events were >1 (vs 0 points/day) and increased with ACB. A 1-point/day increase in ACB was associated with increased risk of UTI, urinary retention, delirium/drowsiness, cognitive impairment, falls/fractures and cardiovascular events for patients with ACB ≤8 points/day preindex. Increasing ACB was associated with increased all-cause total healthcare costs and costs related to cognitive impairment and falls/fractures.

Conclusion

The association between increased ACB and greater risk of certain adverse health outcomes and costs supports the reassessment of anticholinergic medication use for patients with OAB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveCholinergic AntagonistsHealth Care CostsHumansFemaleMaleAgedMiddle AgedProportional Hazards ModelsRetrospective Studies

Stichwörter der Autor:innen

anticholinergicanticholinergic burdencognitive impairmenteconomic burdenfalls/fractureshealthcare resource utilizationoveractive bladder

Substanzen

Cholinergic Antagonists

Autor:innen und Institutionen

  • Department of Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Optum, Eden Prairie, MN 55344, USA.
  • Sumitomo Pharma America, Inc., Marlborough, MA 01752, USA.
  • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • University Hospitals Cleveland Medical Center, Cleveland, OH 44145, USA.
  • Seattle Urology Research Center, Seattle, WA 98040, USA.

ORCID-Profile: Holly E Richter, Benjamin Chastek, Adam Carrera, Christina Steiger, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Roger R Dmochowski, Adonis K Hijaz, Jeffrey Frankel

Zitieren

APA

Richter, H. E., Chastek, B., Carrera, A., Steiger, C., Snyder, D., Abedinzadeh, L., Bancroft, T., Nesheim, J., Dmochowski, R. R., Hijaz, A. K., & Frankel, J. (2026). Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0054

Vancouver

Richter HE, Chastek B, Carrera A, Steiger C, Snyder D, Abedinzadeh L, et al. Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder. Journal of Comparative Effectiveness Research. 2026. doi:10.57264/cer-2025-0054

BibTeX
@article{Richter2026,
  author = {Richter, Holly E and Chastek, Benjamin and Carrera, Adam and Steiger, Christina and Snyder, Daniel and Abedinzadeh, Laleh and Bancroft, Tim and Nesheim, Jeffrey and Dmochowski, Roger R and Hijaz, Adonis K and Frankel, Jeffrey},
  title = {Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  doi = {10.57264/cer-2025-0054}
}
Kostenlos starten →